Value of prostate-specific antigen in the staging of Taiwanese patients with newly diagnosed prostate cancer

Archives of Andrology

Volumn 49, Issue 6, 2003, Pages 471-474

  Meng, E ^a   Sun, G H ^a,b   Wu, S T ^a   Chuang, F P ^a   Lee, S S ^a   Yu, D S ^a   Yen, C Y ^a   Chen, H I ^a   Chang, S Y ^a  

^a NATIONAL DEFENSE UNIVERSITY   (Taiwan)

^b TRI SERVICE GENERAL HOSPITAL   (Taiwan)

Author keywords

Neoplasm staging; Prostate specific antigen; Prostatic neoplasm

Indexed keywords

PROSTATE SPECIFIC ANTIGEN;

ARTICLE; ASIAN; BONE SCINTISCANNING; CANCER DIAGNOSIS; CANCER STAGING; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; HUMAN; MAJOR CLINICAL STUDY; MALE; PELVIS RADIOGRAPHY; PRIORITY JOURNAL; PROSTATE CARCINOMA; PROTEIN BLOOD LEVEL; SCORING SYSTEM; TAIWAN;

EID: 79961203097     PISSN: 01485016     EISSN: None     Source Type: Journal    
DOI: 10.1080/01485010390249971     Document Type: Article

References (22)

1. Albertsen PC, Hanley JA, Harlan LC, Gilliland FD, Hamilton A, Liff JM, et al (2000): The positive yield of imaging studies in the evaluation of men with newly diagnosed prostate cancer: a population based analysis. J Urol 163:1138-1143.
2. American College of Radiology, Expert panel of urologic imaging (1995): Pretreatment Staging of Clinically Localized Prostate Cancer: Appropriateness Criteria. American College of Radiology, ACR Web Site Edition, pp 703-708.
3. American Joint Committee on Cancer (1997): Cancer Staging Manual, 5th ed. Philadelphia: Lipincott-Raven, pp 219-224.
4. Chybowski FM, Keller JJ, Bergstralh EJ, Oesterling JE (1991): Predicting radionuclide bone scan findings in patients with newly diagnosed, untreated prostate cancer: prostate specific antigen is superior to all other clinical parameters. J Urol 145:313-318.
5. Department of Health, Executive Yuan, Republic of China (2002): Cancer Registry Annual Report and Health and Vital Statistics 2001. Taiwan: Department of Health, Executive Yuan, pp 53-103.
6. Flanigan RC, McKay TC, Olson M, Shankey TV, Pyle J, Waters WB (1996): Limited efficacy of preoperative computed tomographic scanning for the evaluation of lymph node metastases in patients before radical prostatectomy. Urology 48:428-432.
7. Fournier GR Jr, Narayan P (1993): Re-evaluation of the need for pelvic lymphadenectomy in low grade prostate cancer. Br J Urol 72:484-488.
8. Gervasi LA, Mata J, Easley JD, Wilbanks JH, Seale-Hawkins C, Carlton CE Jr (1989): Prognostic significance of lymph nodal metastases in prostate cancer. J Urol 142:332-336.
9. Gleave ME, Coupland D, Drachenberg D, Cohen L, Kwong S, Goldenberg SL (1996): Ability of serum prostate specific antigen levels to predict normal bone scans in patients with newly diagnosed prostate cancer. Urology 47:708-712.
10. Kindrick AV, Grossfeld GD, Stier DM, Flanders SC, Henning JM, Carroll PR (1998): Use of imaging tests for staging newly diagnosed prostate cancer: trends from the CaPSURE database. J Urol 160:2102-2106.
11. Landis SH, Murray T, Bolden S, Wingo PA (1998): Cancer Statistics 1998. CA Cancer J Clin 48:6-29.
12. Levran Z, Gonzalez JA, Diokno AC, Jafri SZ, Steinert BW (1995): Are pelvic computed tomography, bone scan, and pelvic lymphadenectomy necessary in the staging of prostatic cancer? Br J Urol 75:778-781.
13. Narayan P, Fournier G, Gajendran V, Leidich R, Lo R, Wolf JS Jr, Jacob G, Nicolaisen G, Palmer K, Freiha F (1994): Utility of preoperative serum prostate-specific antigen concentration and biopsy Gleason score in predicting risk of pelvic lymph node metastases in prostate cancer. Urology 44:519-524.
14. O'Dowd GJ, Veltri RW, Orozco R, Miller MC, Oesterling JE (1997): Update on the appropriate staging evaluation for newly diagnosed prostate cancer. J Urol 158:687-69.
15. Oesterling JE (1991): Prostate specific antigen: a critical assessment of the most useful tumor marker for adenocarcinoma of the prostate. J Urol 145:907-923.
16. Oesterling JE, Martin SK, Bergstralh EJ, Lowe FC (1993): The use of prostate specific antigen in staging patients with newly diagnosed prostate cancer. JAMA 269:57-60.
17. Oesterling, JE (1993): Using PSA to eliminate the staging radionuclide bone scan: significant economic implications. Urol Clin North Am 20:705-711.
18. Parra RO, Isorna S, Perez MG (1996): Radical perineal prostatectomy without pelvic lymphadenectomy: selection criteria and early results. J Urol 155:612-615.
19. Partin AW, Carter HB, Chan DW, Epstein JI, Oesterling JE, Rock RC, Weber JP, Walsh PC (1990): Prostate specific antigen in the staging of localized prostate cancer: influence of tumor differentiation, tumor volume and benign hyperplasia. J Urol 143: 747-752.
20. Petros JA, Catalona WJ (1992): Lower incidence of unsuspected lymph node metastases in 521 consecutive patients with clinically localized prostate cancer. J Urol 147:1574-1575.
21. Stamey TA, Kabalin JN, McNeal JE, Johnstone IM, Freiha F, Redwine EA, Yang N (1989): Prostate specific antigen in the diagnosis and treatment of adenocarcinoma of the prostate, II: radical prostatectomy treated patients. J Urol 141:1076-1083.
22. Wolf JS Jr, Cher M, Dall'era M, Presti JC Jr, Hricak H, Carroll PR (1995): The use and accuracy of cross-sectional imaging and fine needle aspiration cytology for detection of pelvic lymph node metastases before radical prostatectomy. J Urol 153:993-999.